Cellectar Biosciences share price logo

Cellectar Biosciences

NASDAQ: CLRB

$1.23

+0.08

(+6.96%)

Live

as on

Cellectar Biosciences Stock Performance

as on November 7, 2026 at 7:25 am IST

  • Day's Low

    Day's High

    $1.13
    $1.24
    downward going graph

    8.13%

    Downside

    0.81%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.12
    $4.70
    downward going graph

    8.94%

    Downside

    282.11%

    Upside

    downward going graph

Cellectar Biosciences share price movements today

Previous Close
$1.15
Open
$1.13
Volume
443.9K
Market Cap
$12.4M
Day's Low - High
$1.13 - $1.24
52 Week Low - High
$1.12 - $4.70

Cellectar Biosciences Historical Returns

1 Month Return
-26.35 %
3 Month Return
-51.19 %
1 Year Return
-63.17 %
3 Year Return
-98.45 %
5 Year Return
-99.56 %

Cellectar Biosciences Stock Fundamentals & Key Indicators

Check Cellectar Biosciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$12.4M

EPS (TTM)

-4.56

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.29

Industry PE ratio

-3.24

PEG Ratio

-0.00

EBITDA

-22.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-165.71%

Cellectar Biosciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cellectar Biosciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Cellectar Biosciences image
Cellectar Biosciences
Buy$12.4M-99.56%-0.290.00%0.00%
Moderna image
Moderna
Neutral$91.2B9.03%-28.63-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B192.56%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$99.4B52.18%20.7385.77%0.38%

Stock Returns calculator for Cellectar Biosciences Stock including INR - Dollar returns

The Cellectar Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cellectar Biosciences investment value today

Current value as on today

₹39,001

Returns

-₹60,999

(-61%)

Returns from Cellectar Biosciences Stock

-₹63,174 (-63.17%)

Dollar Impact

₹2,175 (+2.17%)

Analyst Recommendation on Cellectar Biosciences Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Cellectar Biosciences. Average target price of $11.5

Cellectar Biosciences Share Price Target

Get share price movements and forecasts by analysts on Cellectar Biosciences.

What analysts predicted

89.3%UPSIDE

Target Price

$11.5

Current Price

$1.23

Analyzed by

1 Analysts

High

$10

Target

$11.50

Low

$10

Cellectar Biosciences target price $11.5, a slight upside of 89.3% compared to current price of $1.23. According to 1 analysts rating.

Indian Investors' Interest in Cellectar Biosciences Stock

Search interest for Cellectar Biosciences Stock has increased by 1359% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:1359% versus previous 30 day period

Cellectar Biosciences Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
-
0
-
Operating Income
-12
-13
-13
-12
-6
-6
-4
-5
-5
-7
EBITDA
-26
0
-14
-2
-6
-5
-4
-5
-5
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-26
0
-14
-2
-6
-5
-4
-5
-5
-6
Income Tax Expense
-
-
-
0
-
-
-
-
-
-
Net Income
-26
0
-14
-2
-6
-5
-4
-5
-5
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Cellectar Biosciences Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
-
Gross Profit
-1
0
0
-
-
-
-
-
0
Operating Income
-13
-13
-14
-15
-24
-28
-38
-51
-22
EBITDA
-12
-13
-13
-14
-23
-31
-42
-44
-21
Interest Expense
0
0
-
-
-
-
-
-
-
Depreciation
1
0
0
0
0
0
0
0
0
Income Before Tax
-13
-13
-14
-15
-24
-31
-42
-44
-21
Income Tax Expense
-
-
-
-
-
0
0
0
-
Net Income
-13
-13
-14
-15
-24
-31
-42
-44
-21
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Cellectar Biosciences Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
0
-14
-2
-6
-5
-4
-5
-5
-6
Operating Cash Flow
-13
-14
-9
-10
-9
-5
-4
-4
-4
-6
Investing Cash Flow
0
0
-
0
-
-
-
0
0
-
Financing Cash Flow
43
0
17
-
-
2
5
4
-
31
Change in Cash
30
-14
8
-10
-9
-2
1
0
-4
25

Cellectar Biosciences Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-13
-13
-14
-15
-24
-28
-42
-44
-21
Operating Cash Flow
-11
-11
-11
-13
-22
-25
-32
-47
-23
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
9
15
9
60
1
9
22
61
13
Change in Cash
-1
3
-2
46
-21
-15
-10
13
-10

Global Institutional Holdings in Cellectar Biosciences

Check out the Institutions with significant holdings in Cellectar Biosciences.

Funds
Holdings
VANGUARD INDEX FUNDS
3.46%
Vanguard
3.29%
Fidelity Concord Street Trust
0.65%
Douglas Swirsky
0.26%
Jarrod Longcor
0.22%
See all

Cellectar Biosciences News & Key Events

  • img

    Today's Timeline - 27 October

    Tue, 02:40 PM

    -

    Cellectar scheduled to report Q3 earnings on 10/29; analysts expect EPS of -$0.56.

    Tue, 06:51 PM

    -

    Cellectar reports durable complete response in a patient with diffuse large B-cell lymphoma treated with iopofosine I 131.

Insights on Cellectar Biosciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 235.0% return, outperforming this stock by 333.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 892.4% return, outperforming this stock by 958.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, CLRB stock has moved down by -54.4%

About Cellectar Biosciences

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
OrganisationCellectar Biosciences
Headquarters100 Campus Drive, Florham Park, NJ, 07932, US
IndustryBiotechnology
CEOJames V. Caruso

Key Management of Cellectar Biosciences

Name

Title

Mr. James V. Caruso

President, CEO & Director

Mr. Chad J. Kolean CPA

VP, CFO & Secretary

Mr. Jarrod Longcor

Chief Operating Officer

FAQs

What is Cellectar Biosciences share price today?

Cellectar Biosciences share price today is $1.23 as on . Cellectar Biosciences share today touched a day high of $1.24 and a low of $1.13.

What is the 52 week high and 52 week low for Cellectar Biosciences share?

Cellectar Biosciences share touched a 52 week high of $4.70 on and a 52 week low of $1.12 on . Cellectar Biosciences stock price today i.e. is trending at $1.23,which is 73.83% down from its 52 week high and 9.82% up from its 52 week low.

What is Cellectar Biosciences's market capitalisation today?

Cellectar Biosciences market capitalisation is $0.00T as on .

How to invest in Cellectar Biosciences Stock (CLRB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cellectar Biosciences on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Cellectar Biosciences Stock (CLRB) from India?

Indian investors can start investing in Cellectar Biosciences (CLRB) shares with as little as ₹93.91000366210938 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.10 in Cellectar Biosciences stock (as per the Rupee-Dollar exchange rate as on ). Based on Cellectar Biosciences share’s latest price of $1.23 as on November 7, 2026 at 1:55 am IST, you will get 8.1301 shares of Cellectar Biosciences. Learn more about fractional shares .

What are the returns that Cellectar Biosciences has given to Indian investors in the last 5 years?

Cellectar Biosciences stock has given -99.56% share price returns and 28.17% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?